Mineralys Presents Lorundrostat Data in Hypertension and CKD Participants

At ASN Kidney Week 2026, Mineralys said lorundrostat reduced blood pressure similarly in Phase 3 participants with and without chronic kidney disease. Among participants with CKD, it reduced albuminuria by 52% versus placebo.